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Stability and reproducibility of 
proteomic profiles measured with 
an aptamer-based platform
Claire H. Kim1,2, Shelley S. Tworoger1,2,3, Meir J. Stampfer1,2,4, Simon T. Dillon5,6, Xuesong Gu5,6,  
Sherilyn J. Sawyer7, Andrew T. Chan  1,8, Towia A. Libermann5,6 & A. Heather Eliassen1,2
The feasibility of SOMAscan, a multiplex, high sensitivity proteomics platform, for use in studies using 
archived plasma samples has not yet been assessed. We quantified 1,305 proteins from plasma samples 
donated by 16 Nurses’ Health Study (NHS) participants, 40 NHSII participants, and 12 local volunteers. 
We assessed assay reproducibility using coefficients of variation (CV) from duplicate samples and intra-
class correlation coefficients (ICC) and Spearman correlation coefficients (r) of samples processed (i.e., 
centrifuged and aliquoted into separate components) immediately, 24, and 48 hours after collection, 
as well as those of samples collected from the same individuals 1 year apart. CVs were <20% for 99% of 
proteins overall and <10% for 92% of proteins in heparin samples compared to 66% for EDTA samples. 
We observed ICC or Spearman r (comparing immediate vs. 24-hour delayed processing) ≥0.75 for 61% 
of proteins, with some variation by anticoagulant (56% for heparin and 70% for EDTA) and protein 
class (ranging from 49% among kinases to 83% among hormones). Within-person stability over 1 year 
was good (ICC or Spearman r ≥ 0.4) for 91% of proteins. These results demonstrate the feasibility of 
SOMAscan for analyses of archived plasma samples.
Protein levels in blood can change as a function of age, health, and environmental exposures and can provide 
important diagnostic, prognostic, and therapeutic information. Therefore, knowing how levels of specific proteins 
are altered by such factors can be a crucial step toward the understanding of disease etiology and may contribute 
to disease prevention and treatment. Examples of well-established protein biomarkers include prostate-specific 
antigen for prostate cancer1, hemoglobin A1c for diabetes mellitus2, and anti-citrullinated protein antibodies 
for rheumatoid arthritis3. Quantification of valid protein biomarkers in a multiplex setting can be technically 
challenging, however, because extremely high sensitivity, specificity, and dynamic range are required to profile 
the human proteome, which consists of an estimated 20,000 proteins as well as splicing and post-translational 
variants that can differ in concentrations by over 10 orders of magnitude4.
High-throughput proteomics technologies have developed rapidly in recent years and have the potential for 
use in biomarker discovery. One such technology is an aptamer-based proteomics platform called SOMAscan 
(SomaLogic, Inc, Boulder, Colorado). Aptamers are single-stranded oligonucleotides which fold into molecular 
structures that bind to proteins with high affinity and specificity in a similar fashion to antibodies4. SOMAscan 
is a highly multiplexed, sensitive platform that uses slow off-rate modified DNA aptamers (SOMAmers) as high 
affinity protein capture reagents to simultaneously quantify more than 1,300 human proteins in all types of pro-
tein extracts, including bodily fluids, tissue, and cells. SOMAscan allows measurement of proteins across a very 
broad dynamic range, from low abundant cytokines to albumin. SOMAscan has been validated in several studies 
which have compared proteomic measurements across different platforms5–11.
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A number of studies published in the last few years have demonstrated the utility of SOMAscan for biomarker 
discovery. Ganz and colleagues used SOMAscan to quantify proteins in plasma samples to develop and validate 
a 9-protein risk score for cardiovascular outcomes among patients with stable coronary heart disease12. Similarly, 
Qiao and colleagues investigated the proteomic profile of hepatocellular carcinoma using SOMAscan and identi-
fied 68 proteins with differential expression between tumor and non-tumor tissues and 8 proteins associated with 
vascular invasion13. The platform has also been applied to discover biomarkers related to many other diseases 
including lung cancer14, mesothelioma15, cancer exosomes16, Alzheimer’s disease17, influenza18, and latent tuber-
culosis infection8.
Despite its potential, this modified aptamer-based proteomics technology has yet to be applied widely to 
archived blood samples from population-based cohort studies. Because the collection and processing (i.e., centri-
fuging and aliquotting into plasma, red blood cells, and white blood cells) of blood samples in such studies often 
do not take place in uniform and ideal conditions, it is critical to know how analytes are influenced by such factors 
as inter-person differences, blood collection protocol, type of anticoagulant used for collection, and processing 
delay19. Furthermore, within-person reproducibility over time of proteomic profiles is valuable information in 
prospective studies of diseases with long latency periods that utilize only a single biological sample from each 
study participant to reflect exposure. Therefore, we conducted the present analysis to examine the feasibility of the 
SOMAscan platform in studies using archived blood samples by assessing the reproducibility of the assay, effect 
of delayed processing of samples, and within-person stability over time. We also performed secondary analyses 
of variations in protein levels by participants’ age, BMI, and fasting status, and compared our results with those 
from previous reports.
Methods
Study Population. The blood samples used in this pilot study included plasma from 16 participants of the 
Nurses’ Health Study (NHS), 40 participants of the NHSII Mind Body Study (MBS), and 12 local volunteers. The 
NHS participants were randomly selected from each of three BMI groups (<25, ≥25 to <30, or ≥30 kg/m2) in 
order to assess the potential association between protein levels and BMI. Plasma samples from local volunteers 
were used to assess assay reproducibility and to compare results by anticoagulant type and sample processing 
delay. The NHSII MBS samples were used to assess within person-stability over a 1-year period.
The NHS began in 1976 with 121,700 female registered nurses between the ages of 30 and 55 years who 
responded to a mailed questionnaire. Of these, 32,826 participants donated their blood samples in 1989–1990. 
Details about the blood collection methods have been reported previously20,21. Briefly, each participant collected 
her blood in two 10 mL sodium heparin tubes and shipped them in a Styrofoam container with an icepack to our 
laboratory via overnight courier. We received 97% of the samples within 26 hours of blood collection.
The NHSII was established in 1989 with 116,429 female registered nurses aged 25 to 42 years. The MBS is 
a sub-study among NHSII participants22. One of the goals of the MBS is to use repeated biological sample col-
lections to evaluate how specific biomarkers fluctuate over time. In the summer of 2013, 226 MBS participants 
collected samples of their hair, toenail, saliva, urine, and blood and shipped them to our laboratory via overnight 
courier. One year later, 208 of the same participants repeated the sample collection procedure. Upon arrival, all 
samples in the NHS and NHSII MBS collection were centrifuged and separated into plasma, red blood cells, and 
white blood cells and stored at −130 °C or below in liquid nitrogen freezers.
Volunteers were recruited using fliers hung around our laboratory and local neighborhoods. They were 
screened for willingness by phone and given an appointment time. At the time of blood draw, all volunteers were 
consented and asked for basic information including age, sex, race/ethnicity, fasting status, smoking status, mul-
tivitamin use, contraceptive use, and pregnancy and breast feeding status. Samples were de-identified at the time 
of draw with links between identifiable donor information and samples permanently broken. Blood samples from 
five local volunteers were collected in sodium heparin tubes, those from another five volunteers were collected 
in EDTA tubes, and those from two volunteers were collected in both types of anticoagulants. Each sample was 
subsequently separated into four aliquots, of which one was processed immediately, two were processed 24 hours 
later, and the last one was processed 48 hours after collection. All blood samples were stored in the same manner 
as described above for the NHS and NHSII samples.
The Institutional Review Board of Brigham and Women’s Hospital approved this study. All research was per-
formed in accordance with relevant guidelines and regulations. Informed consent among the NHS participants 
was implied by receipt of completed questionnaires and blood samples; written informed consent was obtained 
from all MBS participants and local volunteers.
Proteomics Assay. Proteomic profiling was performed using the SOMAscan platform based at the Cancer 
Proteomics Core of Dana-Farber/Harvard Cancer Center (Boston, MA). SOMAscan utilizes single stranded 
DNA-based protein affinity reagents called SOMAmers (Slow Off-rate Modified Aptamers), which are discovered 
in vitro through the SELEX (Systematic Evolution of Ligands by EXponential enrichment) aptamer selection tech-
nology4,23–25. The technology incorporates chemically modified nucleotides that mimic amino acid side chains, 
resulting in a large variety of aptamers with high specificity and affinity (Kd < 1 nM) for their targets23,26. The assay 
transforms the quantity of each protein to be measured into a proportional quantity of a specific SOMAmer, such 
that the end result is a complex mixture of SOMAmers representative of the proteins that were present in the 
original sample. Because SOMAmers are DNA molecules, this resulting mixture can be quantified by standard 
DNA detection techniques such as hybridization to a DNA microarray using relative fluorescence units (RFU) 
as the readout27.
To assay human plasma, the Human Plasma SOMAscan 1.3k kit (SL Part Number 900-00011) was used 
following the manufacturer’s recommended protocol. Plasma samples (50 μL) from local volunteers and those 
from NHS participants were assayed together in one batch and samples from NHSII participants were assayed 
www.nature.com/scientificreports/
3SCIENTIFIC RepoRtS |  (2018) 8:8382  | DOI:10.1038/s41598-018-26640-w
in a second batch. To avoid bias, laboratory personnel were blinded to sample identity, and samples were ran-
domly arranged on the plates, with a set of calibration and normalization samples. Intra-run normalization and 
inter-run calibration were performed according to SOMAscan assay data quality-control procedures as defined 
in the SomaLogic good laboratory practice quality system. Data from all samples passed quality-control criteria 
and were fit for analysis.
Study Design. This pilot study consisted of three parts: a split replicate pilot, a delayed processing pilot, 
and a within-person stability pilot. Detailed information about the characteristics of plasma samples included 
in the study is shown in Table 1. The split replicate pilot was performed to assess assay reproducibility using 14 
sets of replicate samples donated by 12 local volunteers, all of which were processed 24 hours after collection. 
The delayed processing pilot included 36 samples from the same 12 individuals, processed at three different time 
points—0, 24, or 48 hours after collection. The within-person stability pilot included 80 samples from 40 partici-
pants whose blood samples were collected at baseline and again after one year; six blinded quality control samples 
from two local volunteers were also included. The laboratory was blinded to samples from the same person for 
all pilots.
Statistical Analysis. Assay reproducibility and delayed processing stability were examined overall, by anti-
coagulant type, and by protein class. Within-person stability over time was examined overall and by protein class; 
analysis by anticoagulant type was not possible because all samples were collected in sodium heparin tubes. We 
used information obtained from UniProt (www.uniprot.org) to categorize the 1,305 proteins quantified by the 
SOMAscan assay into nine molecular classes—cytokines (N = 138), growth factors (N = 79), kinases (N = 148), 
receptors (N = 258), proteases (N = 168), protease inhibitors (N = 45), hormones (N = 35), structural proteins 
(N = 60), and other/unclassified (N = 499). There were 117 proteins included in more than one category. For 
example, interleukin (IL)-5 and IL-8 were classified as both cytokines and growth factors.
We observed significant clustering of protein levels (i.e., normalized RFU signal values) by batch in principal 
components analysis. Although biologic variability across the samples in the two batches may have contributed, 
significant batch effects were observed even among samples from the same two individuals that were included in 
both batches, which indicated lab variability. Therefore, we adjusted for batch effects using the sva package in R 
and carried out analyses of data from both assays combined using the batch-effect-adjusted data set. Within the 
sva package, the ComBat function directly models and removes known batch effects using empirical Bayes meth-
ods28,29. Protein levels were natural log transformed prior to batch effects adjustment to improve the normality of 
protein level distributions. In our present analysis, adjusting for batch effects had minimal impact on the overall 
Local volunteers 
(n = 12)
NHS 
(n = 16)
NHS II 
(n = 40)
Study Sample Characteristics, N
Total samples collected 56 16 80
Anticoagulant
  EDTA 28 0 0
  Heparin 28 16 80
Split replicates 28 0 0
Processing delay after blood collection
  No delay 12 0 0
  24-hour delay 24 16 80
  48-hour delay 12 0 0
Blood collections over time
  Initial 56 16 40
  Follow-up (1 year after 
initial) 0 0 40
Study Participant Characteristicsa, N(%)
Mean age, years (range) 39 (24–57) 56 (43–68) 60 (53–65)
Female 9 (75.0) 16 (100.0) 40 (100.0)
Time since last meal
  <8 hours 8 (66.7) 5 (31.3) 6 (15.0)
  ≥8 hours 4 (33.3) 11 (68.8) 33 (82.5)
  Unknown 1 (2.5)
BMIb
  <25 kg/m2 5 (31.3) 16 (40.0)
  ≥25 to <30 kg/m2 6 (37.5) 13 (32.5)
  ≥30 kg/m2 5 (31.3) 11 (27.5)
Table 1. Characteristics of study participants and their plasma samples included in proteomic platform pilot 
studies. aFor NHS II study participants, characteristics reported in first blood draw. bBMI information was not 
collected from local volunteers.
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results; however, it may make a difference in larger datasets as might be typical in an analysis of proteomics and 
disease.
Assay reproducibility was quantified using data from the split replicate samples (all of which were processed 
24 hours after collection) and calculating the coefficient of variation (CV) for each participant by dividing the 
standard deviation by the mean protein level and multiplying by 100. Mean CVs were obtained by averaging the 
CVs across individuals for each protein. We also calculated the percentages of proteins with mean CVs < 20% 
and those with mean CVs < 10%. In general, CVs < 20% are considered acceptable and CVs < 10% are consid-
ered very good with respect to laboratory error30. In addition, we calculated Spearman correlation coefficients of 
mean CVs with mean protein levels across the replicates to assess whether assay reproducibility was associated 
with protein level.
The effects of processing delay on proteomic profiling were assessed by calculating Spearman correlation 
coefficients and intraclass correlation coefficients (ICCs). Because we assayed two replicates for samples pro-
cessed 24 hours after collection, we used the average of the duplicate samples in the analysis. Spearman correla-
tion coefficients were used to compare rankings of protein levels in samples processed immediately versus 24 or 
48 hours after collection. ICCs, defined as the between-person variance divided by the sum of the between- and 
within-person variances, were used to assess the impact of within-person variation relative to the total vari-
ation, with higher ICCs representing better stability with delayed processing. To obtain an accurate estimate 
of between-person variability for calculations of ICCs, data from NHS and NHSII (baseline collection only) 
participants were also included. Stability with delayed processing is generally considered excellent if the ICC or 
Spearman correlation coefficient is ≥0.7530.
We also examined within-person stability of protein levels over 1 year by calculating Spearman correlation 
coefficients and ICCs. Data from local volunteers and NHS participants were included in the calculations for 
between-person variability. Within-person reproducibility over time was considered acceptable if the ICC or 
Spearman correlation coefficient was ≥0.430.
We conducted stratified analyses of mean protein levels in NHS, NHSII, and volunteer samples processed 
24 hours after collection by age (<50, 50–59, or ≥60 years old), fasting status (<8 or ≥8 hours), and BMI (<25, 
≥25 to <30, or ≥30 kg/m2) by calculating percentage differences in mean protein levels and identifying individ-
ual proteins that differed most by these factors. Each protein was evaluated for its associations with fasting, age, 
and BMI using a robust variance linear regression model. All models were adjusted for age (continuous) and 
fasting status; BMI was not adjusted for because this variable was not collected from the local volunteers. We 
then calculated the covariate-adjusted geometric mean protein levels in each category by taking the anti-log of 
the marginal mean and calculated the percentage difference compared with the referent group. The percentage of 
proteins with means within 15% of the referent groups’ mean was used as a measure of variability. We repeated 
the stratified analyses after subsetting the proteins to those that passed our pre-established quality control (QC) 
criteria of CV < 20% and ICC or Spearman correlation (immediate vs. 24-hour delayed processing) ≥0.75. We 
applied the Kruskall-Wallis H test on this subset to identify proteins that were expressed differentially (P < 0.01) 
by age (<50 vs. 50–60 vs. ≥60 years) and BMI (<25 vs. 25–30 vs. ≥30 kg/m2) and the Mann-Whitney U test to 
identify those expressed differentially by fasting status (<8 vs. ≥8 hours). We also applied a false discovery rate 
correction of P < 0.05 to mitigate the likelihood of obtaining false positive findings due to multiple comparisons31.
In a secondary analysis, we compared the within-person difference in mean protein levels by anticoagulant 
type using data from the two participants whose plasma samples were collected in both types of anticoagulants. 
Percentage difference was calculated by subtracting the protein levels in EDTA samples from the protein levels 
in heparin samples and dividing the difference by the protein levels in the EDTA samples, multiplied by 100. All 
statistical analyses were performed in R version 3.4.0, except for the robust variance linear regression, which was 
performed using PROC MIXED in SAS version 9.4.
Data availability. The datasets generated and analyzed during the current study are available from the cor-
responding author on reasonable request.
Results
Characteristics of study participants are presented in Table 1. Local volunteers included both men and women, 
and tended to be considerably younger than NHS and NHSII participants. Among all participants, 72% had 
fasted for ≥8 hours at the time of blood collection.
Figure 1 shows the percentages of proteins with mean CV < 10%, 10% ≤ CV < 20%, and CV ≥ 20% overall 
and by anticoagulant (A) and by protein class (B). Overall, 99% of protein analytes had CV < 20% and 83% 
had CV < 10%. Higher proportions of proteins in heparin samples compared with those in EDTA samples had 
CV < 20% (99% vs. 95%) or CV < 10% (92% vs. 66%). At least 98% of the proteins in each protein class had 
CV < 20%. The proportions of proteins with CV < 10% ranged from 75% for kinases to 94% for growth factors 
and hormones. CVs were not significantly correlated with mean protein levels (Spearman r = 0.13).
The ICCs and Spearman r for delayed processing of 24 or 48 hours are shown in Table 2. Among all proteins, 
61% had ICC or Spearman r ≥ 0.75 comparing samples processed immediately versus 24 hours after collection. 
The correlation between samples processed immediately versus 48 hours after collection were generally slightly 
lower than the correlation between samples processed immediately versus 24 hours after collection (Spearman r 
≥0.75, 51% vs. 57%, respectively). The proportion of proteins with ICCs or Spearman r (immediate vs. 24-hour 
delayed processing) ≥0.75 was higher among EDTA samples (70%) than heparin samples (56%) and varied by 
protein class, ranging from 49% among kinases to 83% among hormones. In total, there were 796 proteins that 
passed our pre-established QC criteria of CV < 20% and ICC or Spearman r (immediate vs. 24-hour delayed 
processing) ≥0.75.
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Within-person stability over a 1-year period was very high overall, with 91% of proteins having ICC or 
Spearman r ≥ 0.4 and 72% of proteins having ICC or Spearman r ≥ 0.6 (Table 3). Among the 796 proteins 
that passed our QC criteria, 96% had an ICC or Spearman r ≥ 0.4 and 84% had an ICC or Spearman r ≥ 0.6 
(Supplementary Table S1). Across protein classes, the percentage of proteins with ICC or Spearman r ≥ 0.4 
ranged from 89% among protease inhibitors to 97% among cytokines and hormones; the percentage with ICC 
or Spearman r ≥ 0.6 ranged from 65% among kinases to 82% among growth factors and receptors. Results for 
individual proteins (including mean CVs from the split replicate pilot, ICCs and Spearman r from the delayed 
processing pilot, and ICCs and Spearman r from the within-person stability pilot) are provided in Supplementary 
Table S1.
Figure 1. Split replicates’ mean coefficients of variation. Histograms of the percentage of proteins with mean 
CV < 10%, ≥10% to <20%, and 20% (A) overall and by anticoagulant type; (B) by protein class.
Proteins, N
ICC (0 vs. 24 vs. 48 hr)
Spearman r
(0 vs. 24 hr)
Spearman r
(0 vs. 48 hr)
ICC or  
Spearman r
(0 vs. 24 hr) ≥0.75, %
Median
(10th, 90th 
percentile) ICC ≥ 0.75, %
Median
(10th, 90th 
percentile) r ≥ 0.75, %
Median
(10th, 90th 
percentile) r ≥ 0.75, %
Overall 1,305 0.61(0.00, 0.92) 37
0.80
(0.27, 0.94) 57
0.75
(0.00, 0.93) 51 61
Anticoagulant
  EDTA 1,305 0.71(0.00, 0.95) 46
0.75
(0.32, 0.96) 54
0.68
(0.04, 0.93) 42 70
  Heparin 1,305 0.60(0.00, 0.93) 37
0.64
(−0.18, 0.96) 42
0.61
(−0.29, 0.93) 37 56
Protein Class
  Cytokine 138 0.72(0.00, 0.92) 45
0.84
(0.42, 0.95) 70
0.80
(0.19, 0.94) 62 72
  Growth factor 79 0.74(0.00, 0.93) 48
0.82
(0.20, 0.94) 58
0.79
(0.26, 0.94) 58 65
  Hormone 35 0.76(0.31, 0.95) 51
0.90
(0.68, 0.97) 80
0.83
(0.54, 0.95) 74 83
  Kinase 148 0.41(0.00, 0.92) 31
0.72
(0.13, 0.92) 46
0.64
(−0.23, 0.89) 39 49
  Protease 168 0.64(0.00, 0.90) 38
0.81
(0.33, 0.94) 60
0.76
(0.20, 0.93) 54 67
  Protease inhibitor 45 0.60(0.00, 0.90) 33
0.80
(0.44, 0.95) 51
0.76
(0.40, 0.94) 53 56
  Receptor 258 0.66(0.00, 0.93) 41
0.82
(0.41, 0.94) 64
0.78
(0.25, 0.94) 55 69
  Structural protein 60 0.67(0.00, 0.88) 37
0.80
(0.31, 0.93) 57
0.73
(0.08, 0.92) 48 60
  Other/unclassified 499 0.52(0.00, 0.90) 31
0.75
(0.23, 0.93) 50
0.70
(−0.10, 0.92) 45 54
Table 2. Intra-class and Spearman correlation coefficients for delayed processing by anticoagulant type and 
protein class.
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Overall, the median absolute percentage differences in geometric mean protein levels were <5% when com-
paring each category of age, fasting status, and BMI to the referent group (Table 4). The majority of proteins had 
mean levels within 15% of the referent group. Similar results were observed when the analyses were restricted to 
the proteins that passed our QC criteria. Among the study participants whose BMI data were available, adjusting 
for BMI did not influence the results of mean protein levels by age and fasting status (results not shown).
Heatmaps of proteins whose abundance varied the most (Mann-Whitney U test or Kruskall-Wallis H test 
P < 0.01) by age, fasting status, and BMI are shown in Supplementary Figs S1–S3. After applying a false discov-
ery rate correction of P < 0.05, there were no proteins which differed significantly by age group or fasting status 
but five proteins which differed by BMI—leptin, fatty acid-binding protein (FABP), C-reactive protein (CRP), 
interleukin-1 receptor antagonist protein (IL-1ra), and sex hormone-binding globulin (SHBG).
Within the plasma samples from the two local volunteers whose blood was collected using both heparin and 
EDTA, protein levels were generally lower in the heparin samples than in the EDTA samples at all three process-
ing time points (Supplementary Table S2).
Proteins, N
ICC Spearman r
ICC or 
Spearman 
r ≥ 0.4, %
ICC or 
Spearman 
r ≥ 0.6, %
Median
(10th, 90th 
percentile) ICC ≥ 0.4, %
Median
(10th, 90th 
percentile) r ≥ 0.4, %
Overall 1,305 0.70(0.33, 0.94) 87
0.68
(0.36, 0.87) 87 91 72
Protein Class
  Cytokine 138 0.76(0.51, 0.93) 95
0.70
(0.45, 0.87) 94 97 80
  Growth factor 79 0.78(0.40, 0.94) 90
0.72
(0.40, 0.85) 90 92 82
  Hormone 35 0.75(0.46, 0.93) 91
0.71
(0.44, 0.91) 94 97 80
  Kinase 148 0.68(0.34, 0.94) 86
0.64
(0.32, 0.84) 86 91 65
  Protease 168 0.70(0.33, 0.92) 85
0.70
(0.39, 0.85) 89 92 75
  Protease inhibitor 45 0.72(0.27, 0.89) 87
0.74
(0.42, 0.87) 89 89 78
  Receptor 258 0.77(0.41, 0.96) 91
0.72
(0.44, 0.89) 93 95 82
  Structural protein 60 0.68(0.42, 0.92) 92
0.67
(0.40, 0.87) 90 93 70
  Other/unclassified 499 0.64(0.23, 0.93) 82
0.65
(0.26, 0.86) 82 86 66
Table 3. Intra-class and Spearman correlation coefficients for within-person stability over 1-year period by 
protein class.
Persons, N
All proteins
(N = 1,305)
Proteins with CV < 20% and
ICC or Spearman r (0 vs. 24 hr) ≥0.75
(N = 796)
Median % difference 
(10th, 90th percentiles)
% within ±15% 
of referent
Median % difference 
(10th, 90th percentiles)
% within ±15% 
of referent
Age (years)a
  <50 14 Referent Referent Referent Referent
  50–59 22 −3.7 (−17.6, 14.7) 76 −4.1 (−18.0, 16.9) 73
  ≥60 31 −4.0 (−16.4, 13.3) 79 −3.5 (−16.2, 16.3) 78
Fasting time (hours)b
  <8 19 Referent Referent Referent Referent
  ≥8 48 −1.7 (−13.0, 8.1) 89 −3.4 (−16.1, 7.5) 84
BMI (kg/m2)c
  <25 20 Referent Referent Referent Referent
  ≥25 to 
<30 19 1.1 (−11.9, 14.1) 85 1.2 (−13.5, 17.2) 80
  ≥30 16 −1.7 (−18.2, 17.9) 71 0.4 (−16.6, 23.9) 71
Table 4. Difference in geometric mean protein RFU signal values by age, fasting status, and body mass index. 
aAdjusted for fasting time (<8, ≥8 hours). bAdjusted for age (years, continuous). cAdjusted for age (years, 
continuous) and fasting time (<8, ≥8 hours).
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Discussion
The SOMAscan proteomic platform yielded excellent assay reproducibility and the majority of the protein ana-
lytes remained stable over processing delays of up to 48 hours, with some variations by protein class. Most of the 
proteins also remained stable within the same individuals after one year, with minimal variations by protein class. 
Our findings of high assay reproducibility of the SOMAscan assay on split samples are similar to those reported 
by other groups4,10,32. To our knowledge, this is the first systematic and comprehensive published report on the 
SOMAscan 1.3k platform’s reproducibility over sample processing delays and within-person stability. One prior 
publication evaluated 498 proteins in an early version of SOMAscan (with most of these proteins included in 
version 1.3 k) for protein stability based on processing delays using a different study design from ours33. However, 
EDTA plasma and serum were analyzed from only four volunteers, and no analysis of heparin plasma was per-
formed. Moreover, processing delays were only analyzed up to 20 hours with either 4 hours or 6 hours at room 
temperature and the remainder of the 20-hour processing delay at 4 °C. While the specific analytic process in this 
publication significantly varies from ours, the overall conclusions are consistent with our findings, with ~83% of 
the proteins being stable up to 20 hours of processing delay.
For most proteins measured by this platform, short (24–48 hour) delays in sample processing did not have a 
significant impact on the results of the biomarker, supporting use in studies in which samples cannot be processed 
immediately after collection. In our previous analyses of stability of proteins after 24 or 48 hours of delayed pro-
cessing using singleplex methods, we reported concentrations of follicular stimulating hormone (FSH), prolactin, 
sex-hormone binding globulin, Apolipoprotein (Apo) A-1, and Apo B in cooled blood were very stable, with 
changes ≤1.5% per day34. These proteins were also observed to be stable in the present study, with all proteins 
having ICC or Spearman r (immediate vs. 24-hours delayed processing) ≥0.75 (Supplementary Table S1). In 
another previous study, we reported that adiponectin levels measured by competitive radioimmunoassay were not 
significantly different in blood specimens analyzed after 24 or 36 hours of blood collection compared with those 
which were processed immediately, with an overall ICC of 0.8535. This was in agreement with our present study’s 
observations for adiponectin—overall ICC of samples processed immediately, 24, and 48 hours after blood collec-
tion was 0.94 (results not shown). On the other hand, some proteins, such as insulin-like growth factor (IGF-1), 
had low ICCs due to low between-person variance but acceptable Spearman r values (Supplementary Table S1). 
Further, the choice of anticoagulant for sample collection may depend on the proteins of interest, as previous 
studies (using other platforms) as well as our own have also observed somewhat different proteomic profiles using 
different anticoagulants36–39.
Our results also indicate that, for most of the proteins on the SOMAscan platform, a single measurement 
can reliably estimate average levels over a 1-year period. Among the 796 proteins with acceptable assay repro-
ducibility and delayed processing stability, only 30 showed low within-person stability (i.e., ICC or Spearman 
r < 0.4). Although we observed high levels of within-person stability even among most of the proteins with poor 
delayed processing stability, such proteins should be excluded from subsequent longitudinal analyses given the 
protein concentrations after delay do not adequately reflect circulating concentrations. In our previous study of 
within-person reproducibility over 1 to 2 years of biomarkers measured with a commercially available ELISA40, 
the ICC was 0.82 for soluble leptin receptor, 0.74 for resistin, 0.91 for matrix metalloproteinase (MMP)-1, 0.69 
for MMP2, 0.52 for MMP3, 0.78 for MMP7, and 0.07 for MMP9, which are comparable to the ICCs observed in 
our present analysis—0.97 for soluble leptin receptor, 0.82 for resistin, 0.87 for MMP1, 0.51 for MMP2, 0.84 for 
MMP3, 0.86 for MMP7, and 0.36 for MMP9 (Supplementary Table S1). The level of reproducibility we observed 
for most of the proteins (i.e., ICC or Spearman r ≥ 0.6) is similar to that found for other biological variables such 
as blood pressure (ICC = 0.6)41, blood glucose (ICC = 0.52)42, serum cholesterol (ICC = 0.65)43, and plasma pro-
lactin (ICC = 0.46 to 0.64)44, all exposures considered to be reasonably well-measured and consistent predictors 
of disease. The general stability of proteomic profiles within individuals suggests that a single blood sample is 
adequate to represent an individual’s longer-term exposure for most proteins. The overall stability also suggests 
that alterations of disease-specific sets of proteins may be detectable by comparing longitudinal samples within 
an individual and could be applied for monitoring disease development or progression.
Overall, mean protein levels were not significantly different by age, BMI, or fasting status, although power was 
limited by our relatively small sample size. However, it is important to determine whether we observed similar 
directions of association for biomarkers that have previously been observed to be associated with age, BMI and 
fasting status as this can provide indirect data on the validity of the platform. For example, previous studies have 
reported serum insulin-like growth factor binding protein (IGFBP)-5 levels decrease with age whereas IGFBP-4 
and FSH levels increase with age45–49. In our data, IGFBP-5 decreased with age and FSH increased with age, while 
IGFBP-4 levels did not vary. For BMI, we observed that CRP, sTNF-R1, sTNF-R2, and leptin all were significantly 
positively associated with BMI. This is consistent with multiple prior studies of these markers50–61. We did not 
observe associations by fasting status with insulin, ghrelin, AgRP, leptin, and leptin receptor, which have been 
observed in prior studies62–64. This discrepancy may be due to the fact that the study participants in those prior 
studies had fasted for considerably longer periods compared to those in our present analysis. Overall, we observed 
results consistent with the prior literature for specific biomarker relationships by age and BMI, supporting that 
this platform has good biomarker validity.
Several previous studies have validated SOMAscan using other orthogonal proteomic platforms, including 
LC-MS/MS and ELISA5–11. In an analysis of human embryonic and mesenchymal stem cells, Billing and col-
leagues considered 408 proteins measured by SOMAscan, LC-MS/MS, and RNA sequencing and reported that 
60% of the SOMAscan results were validated by the other two methods, which was comparable to results obtained 
when comparing LC-MS/MS and RNA sequencing to each other5. Murota and colleagues used SOMAscan to 
identify 33 biomarkers associated with rheumatoid arthritis and selected five proteins to validate the results using 
conventional immunoassays, including electrochemiluminescence assays, ELISA, and latex turbidimetric assays6. 
Levels in RFU of SOMAscan were highly correlated with concentrations in conventional assays, with Spearman 
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correlation coefficients ranging between 0.745 and 0.9776. In another study, Coenen-Stass et al. identified 96 
biomarkers associated with Duchenne Muscular Dystrophy in mice using SOMAscan and validated five out of 
six novel markers using ELISA7. The one protein which was not validated was not detectable by ELISA. Moreover, 
Ngo and colleagues developed an aptamer-based immunoaffinity pull down assay combined with LC-MS/MS that 
analytically validated the specificity of SOMAscan-derived aptamers for eight plasma proteins10.
Our study was limited by the relatively small number of samples, resulting in low precision of our estimates. 
For the same reason, the between-person variability may be lower than what it would have been in a larger study, 
suggesting our results for the ICCs may have been underestimated. However, the ICCs were reasonably high for 
the large majority of the markers. Furthermore, because most of our study participants were white females, we 
were not able to investigate whether protein levels and their associations with age, fasting, and BMI differed by 
sex and race.
With the recent advances in proteomics technology, we are now able to collect large amounts of high-quality 
information regarding the human proteome. The results of our pilot study demonstrate the feasibility of 
aptamer-based proteomic profiling technology for use in studies where blood samples may not be collected under 
ideal clinical conditions and may only be collected once from each participant due to cost and logistical reasons. 
Notably, our results show that this proteomics platform has excellent laboratory reproducibility, minimal effect of 
delayed sample processing, and good within-person stability over time, and thus could be considered for use even 
in studies with stored specimens, as is common in many epidemiologic studies. The application of proteomics 
to biomarker research will allow in-depth investigations of the role of individual proteins and protein classes in 
disease etiology, and understanding the intersection of the proteome with other aspects of our biological system, 
such as the genome and metabolome, will bring us closer to the promise of precision medicine.
References
 1. Stamey, T. A. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909–916 
(1987).
 2. The International Expert Committee. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of 
Diabetes. Diabetes Care 32, 1327-1334 (2009).
 3. Rantapää-Dahlqvist, S. et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of 
rheumatoid arthritis. Arthritis Rheum 48, 2741–2749 (2003).
 4. Gold, L. et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. Plos One 5, e15004 (2010).
 5. Billing, A. M. et al. Complementarity of SOMAscan to LC-MS/MS and RNA-seq for quantitative profiling of human embryonic and 
mesenchymal stem cells. J. Proteomics 150, 86–97 (2017).
 6. Murota, A. et al. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of 
rheumatoid arthritis. Cytokine 78, 87–93 (2016).
 7. Coenen-Stass, A. M. et al. Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular 
dystrophy by aptamer-based serum proteomics. Sci. Rep. 5, 17014 (2015).
 8. De Groote, M. A. et al. Highly multiplexed proteomic analysis of Quantiferon supernatants to identify biomarkers of latent 
tuberculosis infection. J. Clin. Microbiol. 55, 391–402 (2017).
 9. Higgins, S. J. et al. Tie2 protects the vasculature against thrombus formation in systemic inflammation. J. Clin. Invest. 128, 1471–1484 
(2018).
 10. Ngo, D. et al. Aptamer-based proteomic profiling reveals novel candidate biomarkers and pathways in cardiovascular disease. 
Circulation. 134, 270–285 (2016).
 11. Hathout, Y. et al. Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children. Sci. Rep. 6, 31727 (2016).
 12. Ganz, P. et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable 
coronary heart disease. JAMA 315, 2532–2541 (2016).
 13. Qiao, Z., Pan, X., Parlayan, C., Ojima, H. & Kondo, T. Proteomic study of hepatocellular carcinoma using a novel modified aptamer-
based array (SOMAscan™) platform. Biochim. Biophys. Acta 1865, 434–443 (2017).
 14. Ostroff, R. M. et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of 
lung cancer. Plos One 5, e15003 (2010).
 15. Ostroff, R. M. et al. Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive 
proteomics-based surveillance tool. PLoS One 7, e46091 (2010).
 16. Webber, J. et al. Proteomics analysis of cancer exosomes using a novel modified aptamer-based array (SOMAscan™) platform. Mol. 
Cell Proteomics 13, 1050–1064 (2014).
 17. Kiddle, S. J. et al. Candidate blood proteome markers of Alzheimer’s disease onset and progression: a systematic review and 
replication study. J. Alzheimers Dis. 38, 515–531 (2014).
 18. Marion, T. et al. Respiratory mucosal proteome quantification in human influenza infections. Plos One 11, e0153674 (2016).
 19. Barelli, S., Crettaz, D., Thadikkaran, L., Rubin, O. & Tissot, J. D. Plasma/serum proteomics: pre-analytical issues. Expert Rev. 
Proteomics 4, 363–370 (2007).
 20. Hankinson, S. E. et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J. Natl. 
Cancer Inst. 87, 1297–1302 (1995).
 21. Hankinson, S. E. et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 
90, 1292–1299 (1998).
 22. Huang, T. et al. Habitual sleep quality and diurnal rhythms of salivary cortisol and dehydroepiandrosterone in postmenopausal 
women. Psychoneuroendocrinology 84, 172–280 (2017).
 23. Davies, D. R. et al. Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. Proc. 
Natl. Acad. Sci. USA 106, 19971–19976 (2012).
 24. Ramaraj, T., Angel, T., Dratz, E. A., Jesaitis, A. J. & Mumey, B. Antigen-antibody interface properties: Composition, residue 
interactions, and features of 53 non-redundant structures. Biochim. Biophys. Acta 1824, 520–532 (2012).
 25. Rohloff, J. C. et al. Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic 
agents. Mol. Ther. Nuc. Acids 3, e201 (2014).
 26. SomaLogic. SOMAmer Technical Note Rev3, http://staging.somalogic.com/wp-content/uploads/2016/09/SSM-017-Rev-3-
SOMAmer-Technical-Note-3-7-15.pdf (2015).
 27. Kraemer, S. et al. From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, 
streamlined multiplex proteomic assay. PLoS One 6, e26332 (2011).
 28. Leek, J. T., Johnson, W. E., Parker, H. S., Jae, A. E. & Storey J. D. The sva package for removing batch effects and other unwanted 
variation in high-throughput experiments. Bioinformatics., https://doi.org/10.1093/bioinformatics/bts034 (2012).
www.nature.com/scientificreports/
9SCIENTIFIC RepoRtS |  (2018) 8:8382  | DOI:10.1038/s41598-018-26640-w
 29. Johnson, W. E. & Li, C. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118–127 
(2007).
 30. Rosner B. Fundementals of Biostatistics (Duxbury Press, 2005).
 31. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. 
Soc. Series B Stat. Methodol. 57, 289–300 (1995).
 32. Candia, J. et al. Assessment of variability in the SOMAscan Assay. Sci. Rep. 7, 14248 (2017).
 33. Ostroff, R. et al. The stability of the circulating human proteome to variations in sample collection and handling procedures 
measured with an aptamer-based proteomics array. J. Proteomics 73, 649–666 (2010).
 34. Hankinson, S. E. et al. Effect of transport conditions on the stability of biochemical markers in blood. Clin. Chem. 35, 2313–2316 
(1989).
 35. Pischon, T., Hotamisligil, G. S. & Rimm, E. B. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. 
Clin. Chem. 49, 650–652 (2003).
 36. Hsieh, S. Y., Chen, R. K., Pan, Y. H. & Lee, H. L. Systematical evaluation of the effects of sample collection procedures on low-
molecular-weight serum/plasma proteome profiling. Proteomics 6, 3189–3198 (2006).
 37. Baumann, S. et al. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 51, 973–980 (2005).
 38. Banks, R. E. et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser 
desorption/ionization mass spectrometry. Clin. Chem. 51, 1637–1649 (2005).
 39. Spencer, K. The influence of different sample collection types on the levels of markers used for Down’s syndrome screening as 
measured by the Kryptor Immunosassay system. Ann. Clin. Biochem. 40, 166–168 (2003).
 40. Kotsopoulos, J. et al. Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the 
Nurses’ Health Studies. Cancer Epidemiol. Biomarkers Prev. 19, 938–946 (2010).
 41. Rosner, B., Hennekens, C. H., Kass, E. H. & Miall, W. E. Age-specific correlation analysis of longitudinal blood pressure data. Am. J. 
Epidemiol. 106, 306–313 (1977).
 42. Gordon, T & Shurtleff, D. The Framingham Study: an epidemiologic investigation of cardiovascular disease. Section 29: Means at 
each examination and inter-examination variation of specified characteristics: Framingham Study Exam 1 to Exam 10. p. DHEW 
Pub No (NIH) 74–478 (1973).
 43. Shekelle, R. B. et al. Diet, serum cholesterol, and death from coronary heart disease. The Western Electric study. N. Engl. J. Med. 304, 
65–70 (1981).
 44. Tworoger, S. S., Eliassen, A. H., Sluss, P. & Hankinson, S. E. A prospective study of plasma prolactin concentrations and risk of 
premenopausal and postmenopausal breast cancer. J. Clin. Oncol 25, 1482–1488 (2007).
 45. Mohan, S. & Baylink, D. J. Serum insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 levels in aging and age-
associated diseases. Endocrine 7, 87–91 (1997).
 46. Reyes, F. I., Winter, J. S. & Faiman, C. Pituitary-ovarian relationships preceding the menopause. A cross-sectional study of serum 
follicle-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels. Am. J. Obstet. Gynecol. 129, 
557–564 (1977).
 47. Sherman, B. M. & Korenman, S. G. Hormonal characteristics of the human menstrual cycle throughout reproductive life. J. Clin. 
Invest. 55, 699–706 (1975).
 48. Lenton, E. A., Sexton, L., Lee, S. & Cooke, I. D. Progressive changes in LH and FSH and LH: FSH ratio in women throughout 
reproductive life. Maturitas 10, 35–43 (1988).
 49. Lee, S. J., Lenton, E. A., Sexton, L. & Cooke, I. D. The effect of age on the cyclical patterns of plasma LH, FSH, oestradiol and 
progesterone in women with regular menstrual cycles. Hum. Reprod. 3, 851–855 (1988).
 50. Pannacciulli, N. et al. C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult 
women. Int. J. Obes. Relat. Metab. Disord. 25, 1416–1420 (2001).
 51. Forouhi, N. G., Sattar, N. & McKeigue, P. M. Relation of C-reactive protein to body fat distribution and features of the metabolic 
syndrome in Europeans and South Asians. Int. J. Obes. Relat. Metab. Disord. 25, 1327–1331 (2001).
 52. Festa, A. et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int. J. Obes. Relat. Metab. Disord. 
25, 1407–1415 (2001).
 53. Zwirska-Korczala, K. et al. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with 
moderate and morbid obesity and metabolic syndrome. J. Physiol. Pharmacol. 58(Suppl 1), 13–35 (2007).
 54. Pai, J. K. et al. Inflammatory markers and the risk of coronary heart disease in men and women. N. Engl. J. Med. 351, 2599–2610 
(2004).
 55. Kern, P. A., Ranganathan, S., Li, C., Wood, L. & Ranganathan, G. Adipose tissue tumor necrosis factor and interleukin-6 expression 
in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 280, E745–E751 (2001).
 56. Hotamisligil, G. S. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J. Intern. Med. 245, 621–625 (1999).
 57. Nilsson, J., Jovinge, S., Niemann, A., Reneland, R. & Lithell, H. Relation between plasma tumor necrosis factor-alpha and insulin 
sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterio. Thromb. Vasc. Biol. 18, 1199–1202 (1998).
 58. Hauner, H., Bender, M., Haastert, B. & Hube, F. Plasma concentrations of soluble TNF-alpha receptors in obese subjects. Int. J. Obes. 
Relat. Metab. Disord. 22, 1239–1243 (1998).
 59. Fernández-Real, J. M. et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 
47, 1757–1762 (1998).
 60. Page-Wilson, G. et al. Proopiomelanocortin, agouti-related protein, and leptin in human cerebrospinal fluid: correlations with body 
weight and adiposity. Am. J. Physiol. Endocrinol. Metab. 309, E458–E465 (2015).
 61. Weigle, D. S. et al. Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels. J. Clin. Endocrinol. Metab. 82, 
561565 (1997).
 62. Page-Wilson, G. et al. Evaluation of CSF and plasma biomarkers of brain melanocortin activity in response to caloric restriction in 
humans. Am. J. Physiol. Endocrinol. Metab. 312, E19–E26 (2016).
 63. Chan, J. L. et al. Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational 
and interventional studies in humans. Diabetes 51, 2105–2112 (2002).
 64. Shen, C. P. et al. Plasma agouti-related protein level: a possible correlation with fasted and fed states in humans and rats. J. 
Neuroendocrinol. 14, 607–610 (2002).
Acknowledgements
This work was supported by the National Institutes of Health (NIH) P30 DK46200. The NHS was funded by NIH 
UM1 CA186107 and R01 CA49449. The NHSII was funded by NIH UM1 CA176726. The MBS was funded by 
NIH R01 CA163451. The DF/HCC Cancer Proteomics Core was funded by NIH P30 CA006516. C.H. Kim was 
funded by NIH T32 CA009001. A.T. Chan was funded by Crohn’s and Colitis Foundation Senior Research Award, 
Stuart and Suzanne Steele MGH Research Scholar Award, and NIH R01 CA137178.
www.nature.com/scientificreports/
1 0SCIENTIFIC RepoRtS |  (2018) 8:8382  | DOI:10.1038/s41598-018-26640-w
Author Contributions
S.T., T.L. and A.H.E. designed the study. S.D., X.G., S.S. and T.L. collected the data. C.K. performed the statistical 
analysis, wrote the manuscript text, and prepared the tables and figures. All authors reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-26640-w.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
